Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic response and progression-free survival among patients with chronic myeloid ...

We evaluated dasatinib, a BCR-ABL inhibitor that targets most imatinib-resistant BCR-ABL mutations, in patients with chronic myelogenous leukemia (CML) or Ph-positive acute lymphoblastic leukemia ...

In the largest prospective trial to date in children with CML-CP, we demonstrate that dasatinib is a safe, effective treatment of pediatric CML-CP. Target responses to first- or second-line dasatinib ...

Recent studies suggest that the Src inhibitor dasatinib blocks these critical cancer cell functions. Because the molecular mechanism of action of dasatinib in breast cancers has not been ...

Aurobindo’s wholly owned subsidiary, Eugia Pharma Specialities, has received the Food and Drug Administration’s permission to ...

Prospective Investigation of Body Mass Index, Colorectal Adenoma, and Colorectal Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Dasatinib safety and efficacy profiles ...

120 (1). While Tyrosine Kinase Inhibitors (TKI), including dasatinib, have profoundly improved clinical outcomes in patients with chronic myeloid leukemia (CML), the bioavailability and systematic ...

WESTON, Fla., Sept. 4, 2024 /PRNewswire/ - Apotex Corp., an affiliate of Apotex Inc. ("Apotex"), announced today the launch of dasatinib tablets, a generic version of Sprycel® 1, in the United ...

Dasatinib Tablets are used for treating newly diagnosed adults with Philadelphia chromosome-positive chronic myeloid leukaemia in the chronic phase. They are also used in adults with chronic ...

This guidance is a Cancer Drugs Fund reconsideration of dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (TA251). This guidance replaces TA251 ...

A new pilot study known as STAMINA (Senolytics To Alleviate Mobility Issues and Neurological Impairments in Aging), that focused on the effects of senolytic medications, Dasatinib and Quercetin ...